Saltar al contenido
Merck

17-10071

Magna GrIP HT96 Rack (for 96 well plates)

for use with separation of magnetic particles from solutions in a 96-well plate

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

UNSPSC Code:
41104923
NACRES:
NB.51
eCl@ss:
32011202
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle


compatibility

for use with separation of magnetic particles from solutions in a 96-well plate

Quality Level

shipped in

ambient

General description

The Magna GrIP HT96 rack is designed for separation of magnetic particles from solutions in a 96-well plate, U-bottom microplates and 0.2 mL PCR plates with no additional accessories. This effective magnetic separation device is composed of white polyoxymethylene (POM) base in standard Society for Biomolecular Screening (SBS) 96-well microplate (12.8cm X 8.6cm) containing 24 (4 x 6) neodymium magnetic rods each having a diameter of approximately 7.5 mm and a Gauss rating of 6000 When a standard 96-well or PCR plate is fitted over the magnetic rack, each magnetic rod sits between four adjacent wells and rapidly pulls magnetic particles to the side or bottom of the wells

Application

Research Category
Epigenetics & Nuclear Function
The Magna GrIP HT96 rack is designed for separation of magnetic particles from solutions in a 96-well plate.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.




Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos


Contenido relacionado

New Products: Antibodies, Assays, Small Molecules, Inhibitors, and Proteins

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).





Número de artículo de comercio global

SKUGTIN
17-1007104053252594892